This is CNBC’s coverage of how U.S. trade partners, industries and employers respond to President Donald Trump’s historic ...

We recently published a list of Jim Cramer’s Take on These 10 Stocks. In this article, we are going to take a look at where ...

Eli Lilly’s stock fell by 2.3% to close at 4:35 PM ET in after-hours trading, while Novo Nordisk’s American depositary receipts saw a decrease of 1.7%. This development came as a surprise to investors ...

Shares of Eli Lilly & Co. LLY shed 6.45% to $738.21 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 5.97% to 5,074.08 and Dow ...

Jim Cramer in a latest program on CNBC urged investors to start accepting the reality of the new economic system under ...

Health care stocks have outperformed so far in 2025 despite uncertainty surrounding the new Donald Trump administration. Health care stocks can often be a solid defensive play in an uncertain economy.

Blair William & Co. IL lifted its stake in Elanco Animal Health Incorporated (NYSE:ELAN – Free Report) by 17.3% during the ...

Gene therapy and gene editing are on the cutting edge of modern biotechnology. Gene therapies are used to correct genetic abnormalities by introducing genetic material at a cellular level and ...

Shares of Eli Lilly & Co, the biggest Big Pharma stock by market capitalization, were not immune to Thursday’s rout caused by ...

Also in this newsletter, the weight-loss drug Mounjaro makes its India debut and stock markets on ‘liberation day’ ...

Eli Lilly & Co. closed 18.86% short of its 52-week high of $972.53, which the company reached on August 22nd.

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.